Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety.
Alison de LimaZ ZelinkovaC van der EntE A P SteegersC J van der WoudePublished in: Gut (2015)
To limit anti-TNF exposure in utero, anti-TNF can be stopped safely in the second trimester in women with IBD in sustained remission. In patients not in sustained remission, anti-TNF may be continued without clear additional risks to the fetus. We observed excellent 1-year child outcomes compared with children from non-IBD controls.
Keyphrases
- rheumatoid arthritis
- ulcerative colitis
- end stage renal disease
- disease activity
- chronic kidney disease
- newly diagnosed
- prognostic factors
- adipose tissue
- physical activity
- metabolic syndrome
- systemic lupus erythematosus
- patient reported outcomes
- skeletal muscle
- climate change
- human health
- replacement therapy
- weight loss